Stock Price Targets and Analyst Ratings

Company	Action	Brokerage	Analyst	Current Price	Price Target	Rating
AAOI Applied Optoelectronics	Target Raised by	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Leopold Subscribe to MarketBeat All Access for the recommendation accuracy rating	$37.82 +16.8%	$17.00 ➝ $39.00	Outperform ➝ Outperform
ABX Barrick Gold	Target Raised by	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		C$22.22 +1.4%	C$21.00	Buy
AC Air Canada	Target Raised by	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		C$21.96 +1.1%	C$25.50 ➝ C$28.00	Buy
ACN Accenture	Target Raised by	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		$366.37 -1.6%	$355.00 ➝ $385.00	Hold ➝ Hold
ACN Accenture	Target Raised by	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		$366.37 -1.6%	$390.00 ➝ $425.00	Market Perform ➝ Market Perform
ACN Accenture	Target Raised by	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	K. Mcveigh Subscribe to MarketBeat All Access for the recommendation accuracy rating	$366.37 -1.6%	$450.00 ➝ $455.00	Buy ➝ Buy
Amazon coin set to soar 25X – starting December 16th? (Ad) This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team of crypto experts has identified it as the most promising crypto of 2024. You can see all of the details surrounding the #1 Crypto of 2024 >3-Cent Amazon Coin<
ADEN ADENTRA	Target Set by	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		$36.64 +2.7%	C$60.00	Strong-Buy
AFRM Affirm	Upgraded by	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Scharf Subscribe to MarketBeat All Access for the recommendation accuracy rating	$65.64 +4.2%	$78.00 ➝ $78.00	Market Perform ➝ Outperform
AFRM Affirm	Upgraded by	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Scharf Subscribe to MarketBeat All Access for the recommendation accuracy rating	$65.64 +4.2%		Hold ➝ Strong-Buy
AIRJ Montana Technologies	Initiated by	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Dayal Subscribe to MarketBeat All Access for the recommendation accuracy rating	$9.50 +0.7%	$12.00	Buy
ALAB Astera Labs	Target Raised by	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		$132.17 +5.5%	$94.00 ➝ $142.00	Overweight ➝ Overweight
ALMS Alumis	Reiterated by	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Kapoor Subscribe to MarketBeat All Access for the recommendation accuracy rating	$8.82 +2.2%	$26.00 ➝ $26.00	Buy ➝ Buy
AMD Advanced Micro Devices	Target Lowered by	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		$119.21 +0.3%	$169.00 ➝ $158.00	Equal Weight ➝ Equal Weight
AMZN Amazon.com	Target Raised by	Tigress Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		$224.92 +0.7%	$245.00 ➝ $290.00	Buy ➝ Buy
ANF Abercrombie & Fitch	Target Raised by	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		$154.56 +0.9%	$201.00 ➝ $204.00	Overweight ➝ Overweight
APLD Applied Digital	Initiated by	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	B. Knoblauch Subscribe to MarketBeat All Access for the recommendation accuracy rating	$8.01 -0.5%	$15.00	Overweight
APLT Applied Therapeutics	Target Lowered by	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	B. Abrahams Subscribe to MarketBeat All Access for the recommendation accuracy rating	$0.88 -13.7%	$4.00 ➝ $1.50	Sector Perform ➝ Sector Perform
APO Apollo Global Management	Target Raised by	Keefe, Bruyette & Woods Subscribe to MarketBeat All Access for the recommendation accuracy rating		$171.03 +0.8%	$168.00 ➝ $196.00	Outperform ➝ Outperform
APR.UN Automotive Properties Real Est Invt TR	Target Set by	National Bankshares Subscribe to MarketBeat All Access for the recommendation accuracy rating		C$11.01 +2.5%	C$13.00	Outperform
AQST Aquestive Therapeutics	Reiterated by	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating		$3.65 +0.3%	$10.00 ➝ $10.00	Buy ➝ Buy
ARES Ares Management	Upgraded by	Keefe, Bruyette & Woods Subscribe to MarketBeat All Access for the recommendation accuracy rating	K. Voigt Subscribe to MarketBeat All Access for the recommendation accuracy rating	$176.04 +2.9%	$166.00 ➝ $202.00	Market Perform ➝ Outperform
AROW Arrow Financial	Initiated by	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	F. Schiraldi Subscribe to MarketBeat All Access for the recommendation accuracy rating	$29.00 +1.2%	$32.00	Neutral
ARWR Arrowhead Pharmaceuticals	Reiterated by	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating		$19.45 -0.3%	$80.00 ➝ $80.00	Buy ➝ Buy
AS Amer Sports	Target Raised by	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	I. Boruchow Subscribe to MarketBeat All Access for the recommendation accuracy rating	$28.18 +2.5%	$20.00 ➝ $25.00	Equal Weight ➝ Equal Weight
ATD Alimentation Couche-Tard	Target Set by	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating		C$80.79 +1.6%	C$91.00	Outperform
ATO Atmos Energy	Upgraded by	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		$139.69 +1.2%	$150.00	Hold ➝ Buy
ATRA Atara Biotherapeutics	Initiated by	Rodman & Renshaw Subscribe to MarketBeat All Access for the recommendation accuracy rating		$11.40 +14.8%	$25.00	Buy
ATRA Atara Biotherapeutics	Upgraded by	RODMAN&RENSHAW Subscribe to MarketBeat All Access for the recommendation accuracy rating	T. Butler Subscribe to MarketBeat All Access for the recommendation accuracy rating	$11.40 +14.8%		Strong-Buy
AVGO Broadcom	Target Raised by	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		$220.79 +1.1%	$233.00 ➝ $265.00	Overweight ➝ Overweight
BAM Brookfield Asset Management	Target Raised by	Keefe, Bruyette & Woods Subscribe to MarketBeat All Access for the recommendation accuracy rating		$54.42 +0.4%	$49.00 ➝ $57.00	Underperform ➝ Underperform
BB BlackBerry	Upgraded by	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		$3.69 +23.8%	$3.25 ➝ $4.00	Hold ➝ Buy
BB BlackBerry	Upgraded by	TD Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Chan Subscribe to MarketBeat All Access for the recommendation accuracy rating	$3.69 +23.8%	$3.25 ➝ $4.00	Hold ➝ Buy
BB BlackBerry	Target Raised by	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		$3.69 +23.8%	$3.00 ➝ $3.50	Neutral ➝ Neutral
BB BlackBerry	Target Raised by	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		$3.69 +23.8%	$2.80 ➝ $3.00	Hold ➝ Hold
BB BlackBerry	Upgraded by	TD Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Chan Subscribe to MarketBeat All Access for the recommendation accuracy rating	C$5.27 +23.1%		Hold ➝ Strong-Buy
BEN Franklin Resources	Target Raised by	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		$20.49 +2.6%	$18.00 ➝ $19.00	Underweight ➝ Underweight
BIIB Biogen	Downgraded by	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	E. Seigerman Subscribe to MarketBeat All Access for the recommendation accuracy rating	$146.47 -0.6%	$230.00 ➝ $164.00	Outperform ➝ Market Perform
BKD Brookdale Senior Living	Reiterated by	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		$5.13 +2.6%	$8.00 ➝ $8.00	Outperform ➝ Outperform
BKD Brookdale Senior Living	Reiterated by	Macquarie Subscribe to MarketBeat All Access for the recommendation accuracy rating		$5.13 +2.6%	$8.00 ➝ $8.00	Outperform ➝ Outperform
BKU BankUnited	Target Lowered by	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		$38.10 +1.8%	$45.00 ➝ $44.00	Equal Weight ➝ Equal Weight
Nvidia’s Bold Move: Tackling Tech’s $1 Trillion Crisis (Ad) Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with … Find out details on these three critical Nvidia partners immediately.
BLK BlackRock	Target Raised by	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		$1,028.69 +1.2%	$1,245.00 ➝ $1,261.00	Overweight ➝ Overweight
BLND Blend Labs	Reiterated by	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		$4.40 -0.7%	$5.75 ➝ $5.75	Buy ➝ Buy
BPOP Popular	Target Raised by	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		$91.66 +1.2%	$110.00 ➝ $115.00	Overweight ➝ Overweight
BRKL Brookline Bancorp	Upgraded by	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Moss Subscribe to MarketBeat All Access for the recommendation accuracy rating	$11.94 +3.6%	$16.00	Market Perform ➝ Strong-Buy
BSIG BrightSphere Investment Group	Target Lowered by	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		$27.01 -3.6%	$26.00 ➝ $25.00	Underweight ➝ Underweight
BX Blackstone	Target Raised by	Keefe, Bruyette & Woods Subscribe to MarketBeat All Access for the recommendation accuracy rating		$170.84 +1.1%	$169.00 ➝ $175.00	Market Perform ➝ Market Perform
CABA Cabaletta Bio	Downgraded by	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	G. Clark-Gartner Subscribe to MarketBeat All Access for the recommendation accuracy rating	$2.38 +3.0%	$15.00 ➝ $6.00	Outperform ➝ Inline
CAC Camden National	Upgraded by	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Moss Subscribe to MarketBeat All Access for the recommendation accuracy rating	$43.42 +2.7%	$50.00	Market Perform ➝ Outperform
CAG Conagra Brands	Target Lowered by	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		$27.11 +1.1%	$31.00 ➝ $29.00	Neutral ➝ Neutral
CAG Conagra Brands	Reiterated by	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		$27.11 +1.1%	$29.00 ➝ $29.00	Sector Perform ➝ Sector Perform
CAS Cascades	Target Raised by	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		C$11.47 +2.0%	C$12.00 ➝ C$13.00	Sector Perform
CBOE Cboe Global Markets	Target Raised by	Keefe, Bruyette & Woods Subscribe to MarketBeat All Access for the recommendation accuracy rating		$191.61 -1.1%	$217.00 ➝ $220.00	Market Perform ➝ Market Perform
CECO CECO Environmental	Target Raised by	Northland Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		$29.49 0.0%	$35.00 ➝ $38.00	Outperform ➝ Outperform
CFP Canfor	Target Lowered by	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		C$14.79	C$21.00 ➝ C$19.00	Outperform
CFX Canfor Pulp Products	Target Lowered by	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		C$0.76	C$1.25 ➝ C$1.00	Sector Perform
CHMG Chemung Financial	Initiated by	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	F. Schiraldi Subscribe to MarketBeat All Access for the recommendation accuracy rating	$50.05 +0.7%	$57.00	Neutral
CHP.UN Choice Properties Real Est Invstmnt Trst	Target Set by	National Bankshares Subscribe to MarketBeat All Access for the recommendation accuracy rating		C$13.35 +1.4%	C$15.50	Sector Perform
CLS Celestica	Target Raised by	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		$95.45 +2.6%	$77.00 ➝ $110.00	Buy
CME CME Group	Target Raised by	Keefe, Bruyette & Woods Subscribe to MarketBeat All Access for the recommendation accuracy rating		$238.53 +0.7%	$237.00 ➝ $260.00	Market Perform ➝ Market Perform
CMPR Cimpress	Reiterated by	Barrington Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		$74.21 +0.7%	$119.00 ➝ $119.00	Outperform ➝ Outperform
COIN Coinbase Global	Target Raised by	Keefe, Bruyette & Woods Subscribe to MarketBeat All Access for the recommendation accuracy rating		$278.71 +1.7%	$165.00 ➝ $275.00	Market Perform ➝ Market Perform
CRC California Resources	Initiated by	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		$50.56 -0.8%	$63.00	Neutral
CRSP CRISPR Therapeutics	Reiterated by	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		$40.72 +0.8%	$86.00 ➝ $86.00	Market Outperform ➝ Market Outperform
CRT.UN CT Real Estate Investment Trust	Target Set by	National Bankshares Subscribe to MarketBeat All Access for the recommendation accuracy rating		C$14.55 +3.2%	C$16.25	Sector Perform
CSL Carlisle Companies	Reiterated by	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		$378.27 +0.1%	$505.00 ➝ $495.00	Outperform ➝ Outperform
CTAS Cintas	Target Lowered by	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		$186.94 +2.3%	$225.00 ➝ $215.00	Buy ➝ Buy
CTAS Cintas	Target Lowered by	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		$186.94 +2.3%	$240.00 ➝ $218.00	Buy ➝ Buy
CTAS Cintas	Target Lowered by	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		$186.94 +2.3%	$209.00 ➝ $200.00	Neutral ➝ Neutral
CTAS Cintas	Target Lowered by	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Haas Subscribe to MarketBeat All Access for the recommendation accuracy rating	$186.94 +2.3%	$191.00 ➝ $184.00	Underweight ➝ Underweight
CTAS Cintas	Reiterated by	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Sabadra Subscribe to MarketBeat All Access for the recommendation accuracy rating	$186.94 +2.3%	$215.00 ➝ $215.00	Sector Perform ➝ Sector Perform
CTAS Cintas	Target Lowered by	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		$186.94 +2.3%	$236.00 ➝ $211.00	Buy ➝ Buy
CVE Cenovus Energy	Target Lowered by	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		C$20.71 +0.2%	C$33.00 ➝ C$32.00	Buy
CYTK Cytokinetics	Reiterated by	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating		$48.87 +4.6%	$120.00 ➝ $120.00	Buy ➝ Buy
DASH DoorDash	Upgraded by	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	K. Ruggeri Subscribe to MarketBeat All Access for the recommendation accuracy rating	$171.00 +2.0%		Hold ➝ Buy
DH Definitive Healthcare	Initiated by	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Garro Subscribe to MarketBeat All Access for the recommendation accuracy rating	$4.18 +1.0%	$5.00	Equal Weight
DLTR Dollar Tree	Reiterated by	Telsey Advisory Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Feldman Subscribe to MarketBeat All Access for the recommendation accuracy rating	$72.94 +5.6%	$75.00 ➝ $75.00	Market Perform ➝ Market Perform
DNTH Dianthus Therapeutics	Initiated by	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Y. Werber Subscribe to MarketBeat All Access for the recommendation accuracy rating	$23.80 +3.3%		Buy
DOCS Doximity	Initiated by	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Garro Subscribe to MarketBeat All Access for the recommendation accuracy rating	$57.83 +4.8%	$55.00	Equal Weight
DRI Darden Restaurants	Target Raised by	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		$187.59 +2.3%	$195.00 ➝ $211.00	Buy ➝ Buy
DRI Darden Restaurants	Target Raised by	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		$187.59 +2.3%	$165.00 ➝ $175.00	Market Perform ➝ Market Perform
DRI Darden Restaurants	Target Raised by	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		$187.59 +2.3%	$195.00 ➝ $210.00	Buy ➝ Buy
DRI Darden Restaurants	Target Raised by	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		$187.59 +2.3%	$190.00 ➝ $205.00	Buy ➝ Buy
DRI Darden Restaurants	Target Raised by	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		$187.59 +2.3%	$195.00 ➝ $200.00	Buy ➝ Buy
DRI Darden Restaurants	Reiterated by	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		$187.59 +2.3%	$182.00 ➝ $200.00	Outperform ➝ Outperform
DRI Darden Restaurants	Target Raised by	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		$187.59 +2.3%	$180.00 ➝ $194.00	Neutral ➝ Neutral
DRI Darden Restaurants	Target Raised by	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating		$187.59 +2.3%	$200.00 ➝ $220.00	Outperform ➝ Outperform
DRI Darden Restaurants	Target Raised by	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Salera Subscribe to MarketBeat All Access for the recommendation accuracy rating	$187.59 +2.3%	$164.00 ➝ $175.00	Equal Weight ➝ Equal Weight
DRI Darden Restaurants	Target Raised by	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		$187.59 +2.3%	$192.00 ➝ $206.00	Overweight ➝ Overweight
DRI Darden Restaurants	Target Raised by	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating		$187.59 +2.3%	$194.00 ➝ $200.00	Overweight ➝ Overweight
EAT Brinker International	Upgraded by	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		$134.26 +2.2%	$70.00 ➝ $115.00	Underweight ➝ Equal Weight
I was wrong. Dead wrong. (Ad) I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. Here’s the full story for you.
ENPH Enphase Energy	Upgraded by	OTR Global Subscribe to MarketBeat All Access for the recommendation accuracy rating		$71.45 +8.6%		Negative ➝ Mixed
ET Energy Transfer	Target Raised by	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		$18.86 +3.2%	$18.00 ➝ $22.00	Overweight ➝ Overweight
EVGO EVgo	Target Lowered by	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		$4.36 +1.9%	$8.00 ➝ $7.00	Overweight ➝ Overweight
EXEL Exelixis	Downgraded by	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	E. Darout Subscribe to MarketBeat All Access for the recommendation accuracy rating	$33.29 -1.2%	$36.00 ➝ $40.00	Outperform ➝ Market Perform
FCEL FuelCell Energy	Target Lowered by	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		$10.42 +11.7%	$15.00 ➝ $8.40	Hold ➝ Hold
FCEL FuelCell Energy	Reiterated by	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		$10.42 +11.7%	$12.00 ➝ $12.00	Hold ➝ Hold
FCEL FuelCell Energy	Target Raised by	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		$10.42 +11.7%	$2.00 ➝ $12.00	Hold
FDS FactSet Research Systems	Reiterated by	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		$483.52 -1.3%	$503.00 ➝ $503.00	Sector Perform ➝ Sector Perform
FDS FactSet Research Systems	Target Raised by	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		$483.52 -1.3%	$469.00 ➝ $493.00	Hold ➝ Hold
FDX FedEx	Target Raised by	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		$275.73 -0.1%	$321.00 ➝ $368.00	Buy ➝ Buy
FDX FedEx	Upgraded by	Loop Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	R. Paterson Subscribe to MarketBeat All Access for the recommendation accuracy rating	$275.73 -0.1%	$288.00 ➝ $365.00	Hold ➝ Buy
FDX FedEx	Target Raised by	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		$275.73 -0.1%	$328.00 ➝ $337.00	Hold ➝ Buy
FDX FedEx	Target Raised by	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Wetherbee Subscribe to MarketBeat All Access for the recommendation accuracy rating	$275.73 -0.1%	$305.00 ➝ $320.00	Equal Weight ➝ Equal Weight
FDX FedEx	Target Raised by	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		$275.73 -0.1%	$366.00 ➝ $370.00	Overweight ➝ Overweight
FDX FedEx	Target Raised by	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		$275.73 -0.1%	$305.00 ➝ $320.00	Outperform ➝ Outperform
FDX FedEx	Target Raised by	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		$275.73 -0.1%	$325.00 ➝ $348.00	Buy ➝ Buy
FDX FedEx	Target Raised by	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		$275.73 -0.1%	$300.00 ➝ $330.00	Market Perform ➝ Market Perform
FDX FedEx	Target Lowered by	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating		$275.73 -0.1%	$350.00 ➝ $345.00	Overweight ➝ Overweight
FDX FedEx	Target Raised by	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		$275.73 -0.1%	$311.00 ➝ $350.00	Buy ➝ Buy
FENC Fennec Pharmaceuticals	Reiterated by	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating		$5.99 +2.6%	$13.00	Outperform
FHN First Horizon	Target Raised by	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		$19.94 +3.5%	$23.00 ➝ $25.00	Overweight ➝ Overweight
FICO Fair Isaac	Initiated by	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		$2,090.98 +2.3%	$2,150.00	Neutral
FISI Financial Institutions	Initiated by	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	F. Schiraldi Subscribe to MarketBeat All Access for the recommendation accuracy rating	$27.12 +1.8%	$33.00	Overweight
FMC FMC	Target Lowered by	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		$50.15 +4.8%	$75.00 ➝ $66.00	Buy ➝ Buy
FNV Franco-Nevada	Target Lowered by	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating		$116.21 +0.9%	$200.00 ➝ $155.00	Buy ➝ Buy
FREY FREYR Battery	Upgraded by	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	G. Lewis Subscribe to MarketBeat All Access for the recommendation accuracy rating	$2.16 +19.3%	$4.00	Neutral ➝ Buy
FRT Federal Realty Investment Trust	Upgraded by	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		$111.92 +2.2%	$122.00 ➝ $125.00	Neutral ➝ Overweight
GIS General Mills	Target Lowered by	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		$63.61 -0.6%	$74.00 ➝ $68.00	Equal Weight ➝ Equal Weight
GOLD Barrick Gold	Target Lowered by	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		$15.46 +1.5%	$23.00 ➝ $17.00	Neutral
GT Goodyear Tire & Rubber	Reiterated by	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		$8.62 +0.3%	$10.00	Hold
GTLS Chart Industries	Target Raised by	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		$184.83 +2.2%	$138.00 ➝ $201.00	Neutral ➝ Neutral
HAL Halliburton	Downgraded by	Griffin Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	K. Simpson Subscribe to MarketBeat All Access for the recommendation accuracy rating	$25.97 +0.8%		Buy ➝ Neutral
HLI Houlihan Lokey	Target Raised by	Keefe, Bruyette & Woods Subscribe to MarketBeat All Access for the recommendation accuracy rating		$173.97 +0.7%	$171.00 ➝ $172.00	Market Perform ➝ Market Perform
HLNE Hamilton Lane	Target Lowered by	Keefe, Bruyette & Woods Subscribe to MarketBeat All Access for the recommendation accuracy rating		$150.68 -0.5%	$215.00 ➝ $167.00	Market Perform ➝ Market Perform
HOOD Robinhood Markets	Target Raised by	Keefe, Bruyette & Woods Subscribe to MarketBeat All Access for the recommendation accuracy rating		$38.33 +3.8%	$24.00 ➝ $38.00	Market Perform ➝ Market Perform
HOOK Hookipa Pharma	Downgraded by	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	B. Abrahams Subscribe to MarketBeat All Access for the recommendation accuracy rating	$2.02 -5.6%	$48.00 ➝ $2.00	Outperform ➝ Sector Perform
HR Healthcare Realty Trust	Downgraded by	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		$16.88 +1.1%	$19.00	Overweight ➝ Neutral
HUMA Humacyte	Reiterated by	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating		$4.64 +34.1%	$12.00 ➝ $15.00	Buy ➝ Buy
HUMA Humacyte	Reiterated by	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating		$4.64 +34.1%	$25.00 ➝ $25.00	Buy ➝ Buy
IBKR Interactive Brokers Group	Target Raised by	Keefe, Bruyette & Woods Subscribe to MarketBeat All Access for the recommendation accuracy rating	K. Voigt Subscribe to MarketBeat All Access for the recommendation accuracy rating	$175.92 +1.2%	$152.00 ➝ $190.00	Market Perform ➝ Market Perform
IBRX ImmunityBio	Reiterated by	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating		$2.62 -1.9%	$30.00 ➝ $30.00	Buy ➝ Buy
IFP Interfor	Target Lowered by	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		C$16.83 +0.8%	C$27.00 ➝ C$26.00	Outperform
IFRX InflaRx	Reiterated by	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating		$2.24 +5.2%	$8.00 ➝ $8.00	Buy ➝ Buy
IIPR Innovative Industrial Properties	Downgraded by	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		$73.66 -22.7%	$118.00 ➝ $70.00	Neutral ➝ Underweight
IIPR Innovative Industrial Properties	Downgraded by	Compass Point Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Ross Subscribe to MarketBeat All Access for the recommendation accuracy rating	$73.66 -22.7%	$125.00 ➝ $78.00	Buy ➝ Neutral
INSG Inseego	Target Lowered by	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		$10.81 -0.6%	$17.00 ➝ $12.00	Hold ➝ Hold
INVZ Innoviz Technologies	Upgraded by	Rosenblatt Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	K. Cassidy Subscribe to MarketBeat All Access for the recommendation accuracy rating	$1.15 +9.5%	$3.25 ➝ $4.00	Neutral ➝ Buy
IONQ IonQ	Target Raised by	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating		$44.42 +17.6%	$22.00 ➝ $45.00	Buy ➝ Buy
IONS Ionis Pharmaceuticals	Reiterated by	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating		$35.63 +0.1%		Outperform
IONS Ionis Pharmaceuticals	Reiterated by	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating		$35.63 +0.1%	$60.00 ➝ $60.00	Buy ➝ Buy
Is Starlink Set For The Largest IPO In History? (Ad) He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000! Click here now for the urgent details.
IQV IQVIA	Initiated by	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Garro Subscribe to MarketBeat All Access for the recommendation accuracy rating	$197.27 +3.0%	$250.00	Overweight
IREN Iris Energy	Initiated by	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	G. Lewis Subscribe to MarketBeat All Access for the recommendation accuracy rating	$11.81 +3.5%	$33.00	Buy
IVZ Invesco	Target Raised by	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		$17.33 +3.3%	$18.00 ➝ $19.00	Equal Weight ➝ Equal Weight
IVZ Invesco	Target Lowered by	Keefe, Bruyette & Woods Subscribe to MarketBeat All Access for the recommendation accuracy rating		$17.33 +3.3%	$19.00 ➝ $18.00	Market Perform ➝ Market Perform
JBL Jabil	Target Raised by	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		$145.00 +3.2%	$157.00 ➝ $179.00	Overweight ➝ Overweight
JCI Johnson Controls International	Upgraded by	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Eade Subscribe to MarketBeat All Access for the recommendation accuracy rating	$80.64 +2.5%	$88.00	Hold ➝ Buy
JHG Janus Henderson Group	Target Raised by	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		$42.55 +2.0%	$46.00 ➝ $48.00	Equal Weight ➝ Equal Weight
JRVR James River Group	Target Lowered by	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		$4.61 +1.3%	$11.00 ➝ $8.00	Market Outperform ➝ Market Outperform
KIM Kimco Realty	Downgraded by	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		$23.42 +1.8%	$26.00	Overweight ➝ Neutral
KKR KKR & Co. Inc.	Target Raised by	Keefe, Bruyette & Woods Subscribe to MarketBeat All Access for the recommendation accuracy rating		$147.58 +2.8%	$163.00 ➝ $170.00	Outperform ➝ Outperform
KMX CarMax	Target Raised by	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		$84.27 +0.0%	$72.00 ➝ $88.00	Hold ➝ Hold
KMX CarMax	Target Raised by	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		$84.27 +0.0%	$70.00 ➝ $72.00	Underweight ➝ Underweight
KMX CarMax	Target Raised by	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		$84.27 +0.0%	$72.00 ➝ $80.00	Neutral ➝ Neutral
KMX CarMax	Target Raised by	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating		$84.27 +0.0%	$90.00 ➝ $98.00	Buy ➝ Buy
KR Kroger	Target Raised by	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		$61.85 +1.5%	$70.00 ➝ $75.00	Buy ➝ Buy
KRC Kilroy Realty	Upgraded by	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		$40.50 +4.1%	$45.00 ➝ $49.00	Neutral ➝ Overweight
LAZ Lazard	Downgraded by	Keefe, Bruyette & Woods Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Hall Subscribe to MarketBeat All Access for the recommendation accuracy rating	$52.04 +3.1%	$65.00 ➝ $57.00	Outperform ➝ Market Perform
LCNB LCNB	Initiated by	Hovde Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	B. Nosal Subscribe to MarketBeat All Access for the recommendation accuracy rating	$15.24 -3.0%	$16.25	Market Perform
LEN Lennar	Downgraded by	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Reichardt Subscribe to MarketBeat All Access for the recommendation accuracy rating	$138.08 -0.2%		Buy ➝ Neutral
LEN Lennar	Target Lowered by	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Bouley Subscribe to MarketBeat All Access for the recommendation accuracy rating	$138.08 -0.2%	$181.00 ➝ $135.00	Equal Weight ➝ Equal Weight
LEN Lennar	Target Lowered by	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		$138.08 -0.2%	$225.00 ➝ $205.00	Buy ➝ Buy
LEN Lennar	Target Lowered by	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		$138.08 -0.2%	$160.00 ➝ $130.00	Underperform ➝ Underperform
LEN Lennar	Target Lowered by	Keefe, Bruyette & Woods Subscribe to MarketBeat All Access for the recommendation accuracy rating		$138.08 -0.2%	$210.00 ➝ $170.00	Outperform ➝ Outperform
LGO Largo	Reiterated by	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating		$1.70 +1.8%	$4.20 ➝ $4.20	Buy ➝ Buy
LINE Lineage	Downgraded by	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		$58.57 +2.9%	$78.00 ➝ $75.00	Overweight ➝ Neutral
LPLA LPL Financial	Target Raised by	Keefe, Bruyette & Woods Subscribe to MarketBeat All Access for the recommendation accuracy rating		$327.93 +0.1%	$325.00 ➝ $390.00	Outperform ➝ Outperform
LQDA Liquidia	Initiated by	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	T. Fauth Subscribe to MarketBeat All Access for the recommendation accuracy rating	$11.10 +4.8%	$20.00	Overweight
LUMN Lumen Technologies	Reiterated by	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		$5.92 -2.3%	$4.00 ➝ $4.25	Sector Perform ➝ Sector Perform
LVTX LAVA Therapeutics	Target Lowered by	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating		$1.03 +4.2%	$6.00 ➝ $2.00	Buy ➝ Buy
LW Lamb Weston	Target Lowered by	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		$62.09 -0.7%	$80.00 ➝ $68.00	Hold ➝ Hold
LW Lamb Weston	Downgraded by	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	T. Palmer Subscribe to MarketBeat All Access for the recommendation accuracy rating	$62.09 -0.7%	$90.00 ➝ $68.00	Buy ➝ Neutral
LXP LXP Industrial Trust	Reiterated by	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		$8.32 +1.2%		Market Perform ➝ Market Perform
MC Moelis & Company	Upgraded by	Keefe, Bruyette & Woods Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Hall Subscribe to MarketBeat All Access for the recommendation accuracy rating	$73.81 +2.9%	$71.00 ➝ $86.00	Market Perform ➝ Outperform
MCO Moody's	Initiated by	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	P. Christiansen Subscribe to MarketBeat All Access for the recommendation accuracy rating	$466.35 +0.9%	$565.00	Buy
MIDD Middleby	Reiterated by	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		$134.72 +1.5%	$155.00 ➝ $155.00	Buy ➝ Buy
MKTX MarketAxess	Target Lowered by	Keefe, Bruyette & Woods Subscribe to MarketBeat All Access for the recommendation accuracy rating		$230.15 +0.7%	$276.00 ➝ $255.00	Market Perform ➝ Market Perform
MNKD MannKind	Initiated by	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	T. Fauth Subscribe to MarketBeat All Access for the recommendation accuracy rating	$6.85 +8.7%	$9.00	Overweight
MNMD Mind Medicine (MindMed)	Initiated by	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	R. Li Subscribe to MarketBeat All Access for the recommendation accuracy rating	$7.16 +2.1%	$20.00	Buy
MPAA Motorcar Parts of America	Initiated by	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Soderberg Subscribe to MarketBeat All Access for the recommendation accuracy rating	$7.91 +1.3%	$14.00	Overweight
MRK Merck & Co., Inc.	Downgraded by	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	E. Seigerman Subscribe to MarketBeat All Access for the recommendation accuracy rating	$98.05 -1.5%	$136.00 ➝ $105.00	Outperform ➝ Market Perform
MRVL Marvell Technology	Target Raised by	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		$111.90 +2.6%	$102.00 ➝ $120.00	Equal Weight ➝ Equal Weight
MU Micron Technology	Target Lowered by	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		$90.12 +3.5%	$145.00 ➝ $110.00	Overweight ➝ Overweight
NBIX Neurocrine Biosciences	Reiterated by	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating		$135.42 +0.3%		Hold ➝ Hold
NDAQ Nasdaq	Target Raised by	Keefe, Bruyette & Woods Subscribe to MarketBeat All Access for the recommendation accuracy rating		$77.70 +0.4%	$86.00 ➝ $91.00	Outperform ➝ Outperform
NKE NIKE	Target Lowered by	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		$76.94 -0.2%	$79.00 ➝ $75.00	Hold ➝ Hold
NKE NIKE	Target Lowered by	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Civello Subscribe to MarketBeat All Access for the recommendation accuracy rating	$76.94 -0.2%	$97.00 ➝ $90.00	Buy ➝ Buy
NKE NIKE	Target Lowered by	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Sole Subscribe to MarketBeat All Access for the recommendation accuracy rating	$76.94 -0.2%	$80.00 ➝ $73.00	Neutral ➝ Neutral
NKE NIKE	Downgraded by	Telsey Advisory Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Fernandez Subscribe to MarketBeat All Access for the recommendation accuracy rating	$76.94 -0.2%	$93.00 ➝ $80.00	Outperform ➝ Market Perform
NKE NIKE	Target Lowered by	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		$76.94 -0.2%	$80.00 ➝ $74.00	Equal Weight ➝ Equal Weight
NKE NIKE	Target Lowered by	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		$76.94 -0.2%	$95.00 ➝ $90.00	Buy ➝ Buy
URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad) All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen. Register for the FREE Workshop Now & get $10 in Bitcoin
NKE NIKE	Reiterated by	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	T. Nikic Subscribe to MarketBeat All Access for the recommendation accuracy rating	$76.94 -0.2%	$84.00 ➝ $84.00	Buy ➝ Buy
NKE NIKE	Target Lowered by	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Yih Subscribe to MarketBeat All Access for the recommendation accuracy rating	$76.94 -0.2%	$79.00 ➝ $70.00	Equal Weight ➝ Equal Weight
NOW ServiceNow	Target Raised by	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		$1,091.25 +1.5%	$1,000.00 ➝ $1,200.00	Buy ➝ Buy
NRIM Northrim BanCorp	Initiated by	Hovde Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	B. Rabatin Subscribe to MarketBeat All Access for the recommendation accuracy rating	$76.48 -0.8%	$96.50	Outperform
NUS Nu Skin Enterprises	Target Lowered by	DA Davidson Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Xue Subscribe to MarketBeat All Access for the recommendation accuracy rating	$6.60 -3.9%	$11.00 ➝ $7.00	Neutral ➝ Neutral
ONB Old National Bancorp	Target Raised by	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		$21.50 +2.1%	$26.00 ➝ $27.00	Overweight ➝ Overweight
OPRX OptimizeRx	Initiated by	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Garro Subscribe to MarketBeat All Access for the recommendation accuracy rating	$4.91 +3.4%	$5.50	Equal Weight
ORCL Oracle	Downgraded by	Monness Crespi & Hardt Subscribe to MarketBeat All Access for the recommendation accuracy rating	B. White Subscribe to MarketBeat All Access for the recommendation accuracy rating	$169.66 +0.5%	$130.00	Neutral ➝ Sell
ORKA Oruka Therapeutics	Reiterated by	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Kapoor Subscribe to MarketBeat All Access for the recommendation accuracy rating	$20.31 -2.2%	$45.00 ➝ $45.00	Buy ➝ Buy
OWL Blue Owl Capital	Target Raised by	Keefe, Bruyette & Woods Subscribe to MarketBeat All Access for the recommendation accuracy rating		$23.49 +1.7%	$22.00 ➝ $26.00	Market Perform ➝ Market Perform
PAYS Paysign	Initiated by	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating		$2.99 +2.0%	$6.00	Buy
PAYX Paychex	Reiterated by	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		$139.54 +1.3%	$148.00 ➝ $148.00	Sector Perform ➝ Sector Perform
PB Prosperity Bancshares	Target Raised by	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		$74.95 +1.1%	$84.00 ➝ $88.00	Equal Weight ➝ Equal Weight
PBF PBF Energy	Downgraded by	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Gabelman Subscribe to MarketBeat All Access for the recommendation accuracy rating	$25.15 -1.2%	$27.00 ➝ $20.00	Hold ➝ Sell
PCVX Vaxcyte	Initiated by	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Shibutani Subscribe to MarketBeat All Access for the recommendation accuracy rating	$86.53 +0.4%	$135.00	Buy
PFLT PennantPark Floating Rate Capital	Initiated by	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	R. Dodd Subscribe to MarketBeat All Access for the recommendation accuracy rating	$10.68 -0.3%		Market Perform
PGY Pagaya Technologies	Initiated by	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		$8.95 +2.8%	$33.00 ➝ $11.00	Neutral ➝ Neutral
PJT PJT Partners	Target Raised by	Keefe, Bruyette & Woods Subscribe to MarketBeat All Access for the recommendation accuracy rating		$155.41 +1.7%	$151.00 ➝ $159.00	Market Perform ➝ Market Perform
PRTA Prothena	Initiated by	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	R. Li Subscribe to MarketBeat All Access for the recommendation accuracy rating	$15.22 -4.9%	$40.00	Buy
PRTA Prothena	Reiterated by	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating		$15.22 -4.9%	$84.00 ➝ $48.00	Buy ➝ Buy
PSNL Personalis	Reiterated by	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating		$5.75 +9.3%	$7.25 ➝ $7.25	Buy ➝ Buy
PSNL Personalis	Target Raised by	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating		$5.75 +9.3%	$9.00 ➝ $11.00	Buy ➝ Buy
PYXS Pyxis Oncology	Reiterated by	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		$1.69 +9.7%	$10.00 ➝ $8.00	Outperform ➝ Outperform
PYXS Pyxis Oncology	Reiterated by	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating		$1.69 +9.7%	$7.00 ➝ $5.00	Buy ➝ Buy
QBTS D-Wave Quantum	Target Raised by	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating		$6.44 +1.1%	$2.50 ➝ $9.00	Buy ➝ Buy
QBTS D-Wave Quantum	Target Raised by	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating		$6.44 +1.1%	$3.00 ➝ $8.00	Buy ➝ Buy
RARE Ultragenyx Pharmaceutical	Target Raised by	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		$44.22 +1.7%	$75.00 ➝ $88.00	Overweight ➝ Overweight
RDDT Reddit	Initiated by	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Morris Subscribe to MarketBeat All Access for the recommendation accuracy rating	$170.71 +4.3%	$210.00	Buy
RDDT Reddit	Target Raised by	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		$170.71 +4.3%	$120.00 ➝ $200.00	Buy ➝ Buy
RGTI Rigetti Computing	Initiated by	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	R. Shannon Subscribe to MarketBeat All Access for the recommendation accuracy rating	$9.37 +25.4%	$12.00	Buy
RJF Raymond James	Target Raised by	Keefe, Bruyette & Woods Subscribe to MarketBeat All Access for the recommendation accuracy rating		$155.05 +2.8%	$143.00 ➝ $170.00	Market Perform ➝ Market Perform
RNA Avidity Biosciences	Initiated by	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Ghosh Subscribe to MarketBeat All Access for the recommendation accuracy rating	$31.82 +2.5%	$72.00	Buy
RXST RxSight	Downgraded by	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		$33.66 -11.9%	$65.00 ➝ $40.00	Buy ➝ Hold
RYTM Rhythm Pharmaceuticals	Initiated by	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		$56.12 +1.2%	$76.00	Outperform
RZLV Rezolve AI	Reiterated by	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating		$2.96 -2.6%	$8.00 ➝ $8.00	Buy ➝ Buy
SCHW Charles Schwab	Target Raised by	Keefe, Bruyette & Woods Subscribe to MarketBeat All Access for the recommendation accuracy rating	K. Voigt Subscribe to MarketBeat All Access for the recommendation accuracy rating	$74.31 +0.9%	$81.00 ➝ $93.00	Outperform ➝ Outperform
SEIC SEI Investments	Target Raised by	Keefe, Bruyette & Woods Subscribe to MarketBeat All Access for the recommendation accuracy rating		$82.75 +1.6%	$76.00 ➝ $86.00	Market Perform ➝ Market Perform
SFTBY SoftBank Group	Downgraded by	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		$28.19 -2.8%		Buy ➝ Hold
SLB Schlumberger	Downgraded by	Griffin Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	K. Simpson Subscribe to MarketBeat All Access for the recommendation accuracy rating	$36.83 -0.2%		Buy ➝ Neutral
SMCI Super Micro Computer	Upgraded by	Northland Capmk Subscribe to MarketBeat All Access for the recommendation accuracy rating	N. Chokshi Subscribe to MarketBeat All Access for the recommendation accuracy rating	$31.59 +1.1%		Strong-Buy
SPGI S&P Global	Initiated by	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	P. Christiansen Subscribe to MarketBeat All Access for the recommendation accuracy rating	$491.81 +1.1%	$600.00	Buy
SPRO Spero Therapeutics	Downgraded by	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		$0.96 -4.3%	$5.00 ➝ $5.00	Outperform ➝ In-Line
SR Spire	Upgraded by	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	G. Moreen Subscribe to MarketBeat All Access for the recommendation accuracy rating	$66.69 +1.7%	$65.00 ➝ $76.00	Neutral ➝ Outperform
STEP STEP Energy Services	Target Lowered by	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		C$4.18 -14.9%	C$6.25 ➝ C$6.00	Outperform
STOK Stoke Therapeutics	Initiated by	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	R. Li Subscribe to MarketBeat All Access for the recommendation accuracy rating	$11.68 +3.4%	$24.00	Buy
STT State Street	Upgraded by	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		$98.20 +2.9%	$95.00	Underweight ➝ Neutral
STZ Constellation Brands	Reiterated by	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	G. Pascarelli Subscribe to MarketBeat All Access for the recommendation accuracy rating	$227.63 +0.3%	$280.00 ➝ $280.00	Buy ➝ Buy
SU Suncor Energy	Reiterated by	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		$34.50 -0.3%	$66.00 ➝ $66.00	Outperform ➝ Outperform
SU Suncor Energy	Target Lowered by	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		C$49.60 -0.4%	C$62.00 ➝ C$54.00	Hold
SVRA Savara	Initiated by	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	T. Fauth Subscribe to MarketBeat All Access for the recommendation accuracy rating	$3.23	$8.00	Overweight
TEAM Atlassian	Target Raised by	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		$257.26 +2.4%	$255.00 ➝ $285.00	Buy ➝ Buy
TMP Tompkins Financial	Initiated by	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	F. Schiraldi Subscribe to MarketBeat All Access for the recommendation accuracy rating	$69.38 +2.2%	$70.00	Neutral
TPG TPG	Target Raised by	Keefe, Bruyette & Woods Subscribe to MarketBeat All Access for the recommendation accuracy rating		$64.82 +1.3%	$62.00 ➝ $70.00	Market Perform ➝ Market Perform
TROW T. Rowe Price Group	Target Raised by	Keefe, Bruyette & Woods Subscribe to MarketBeat All Access for the recommendation accuracy rating		$116.12 +2.8%	$114.00 ➝ $116.00	Market Perform ➝ Market Perform
TROW T. Rowe Price Group	Target Raised by	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		$116.12 +2.8%	$129.00 ➝ $132.00	Equal Weight ➝ Equal Weight
TTC Toro	Target Lowered by	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		$81.48 +0.5%	$100.00 ➝ $95.00	Outperform ➝ Outperform
USNA USANA Health Sciences	Upgraded by	DA Davidson Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Xue Subscribe to MarketBeat All Access for the recommendation accuracy rating	$33.38 -3.8%		Hold
VCTR Victory Capital	Target Raised by	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		$65.46 +4.6%	$64.00 ➝ $66.00	Equal Weight ➝ Equal Weight
VEEV Veeva Systems	Initiated by	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Garro Subscribe to MarketBeat All Access for the recommendation accuracy rating	$224.15 +2.0%	$280.00	Overweight
VERU Veru	Reiterated by	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating		$0.65 +3.3%	$3.00 ➝ $3.00	Buy ➝ Buy
VET Vermilion Energy	Target Lowered by	TD Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		C$12.73 -0.2%	C$18.00 ➝ C$17.00	Buy
VITL Vital Farms	Initiated by	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	E. Lauriers Subscribe to MarketBeat All Access for the recommendation accuracy rating	$39.69 +2.5%	$50.00	Buy
VRCA Verrica Pharmaceuticals	Reiterated by	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Belanger Subscribe to MarketBeat All Access for the recommendation accuracy rating	$0.69 +2.6%		Hold ➝ Hold
VRTS Virtus Investment Partners	Target Raised by	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		$221.00 +1.4%	$224.00 ➝ $228.00	Underweight ➝ Underweight
VRTX Vertex Pharmaceuticals	Target Lowered by	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		$397.27 +0.2%	$566.00 ➝ $520.00	Outperform ➝ Outperform
VRTX Vertex Pharmaceuticals	Reiterated by	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating		$397.27 +0.2%		Hold ➝ Hold
VRTX Vertex Pharmaceuticals	Target Lowered by	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating		$397.27 +0.2%	$600.00 ➝ $535.00	Buy ➝ Buy
VRTX Vertex Pharmaceuticals	Target Lowered by	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	G. Wang Subscribe to MarketBeat All Access for the recommendation accuracy rating	$397.27 +0.2%	$509.00 ➝ $418.00	Equal Weight ➝ Equal Weight
VTEX VTEX	Target Lowered by	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		$5.68 -2.7%	$12.50 ➝ $11.00	Buy ➝ Buy
VTR Ventas	Target Raised by	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		$58.76 +1.8%	$65.00 ➝ $66.00	Neutral ➝ Neutral
VVV Valvoline	Initiated by	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		$36.55 +0.8%	$42.00	Hold
VZ Verizon Communications	Target Raised by	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		$39.93 -0.1%	$44.00 ➝ $45.00	Neutral ➝ Neutral
WFRD Weatherford International	Target Lowered by	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		$67.10 -2.1%	$110.00 ➝ $95.00	Buy ➝ Buy
WOOF Petco Health and Wellness	Reiterated by	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		$3.96 +0.8%	$6.00 ➝ $6.00	Outperform ➝ Outperform
WTW Willis Towers Watson Public	Upgraded by	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		$317.57 +2.1%	$352.00 ➝ $382.00	Hold ➝ Buy
X United States Steel	Target Lowered by	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	K. Jancic Subscribe to MarketBeat All Access for the recommendation accuracy rating	$30.14 -5.0%	$43.00 ➝ $40.00	Outperform ➝ Outperform
XMTR Xometry	Reiterated by	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Devitt Subscribe to MarketBeat All Access for the recommendation accuracy rating	$41.67 +13.9%	$48.00	Outperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 12:07 PM ET.

(Ad)

I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Stock Ratings and Recommendations: Understanding Analyst Ratings

Written by MarketBeat Staff

July 5, 2023

Key Points

Stock analysts give ratings to companies based on their research and insights.
Analysis comes from the buy side (fund companies, investment managers) or sell side (brokers, banks).
Analysts use different methodologies, so investors should always look into why a particular rating was given.
5 stocks we like better than EXA)

You'll often hear a particular stock called a "buy" or "sell," but who exactly makes these calls? Ratings and recommendations come from stock analysts, who research different securities and work for various institutions, brokerage firms and other financial companies.

Analyst ratings are designed to give additional information to investors beyond just what the company is saying, but are analyst ratings reliable? In this article, we'll discuss how to read analyst ratings, what goes into their decision-making process and how potential conflicts of interest influence analyst stock ratings.

What Are Analyst Ratings?

A stock rating is a simple heuristic given by analysts who review the firm's financial statements, listen to conference calls, chat with company executives and compare the stock to others in the industry or sector. Finally, an analyst uses all this information to produce a simple recommendation and price target.

When a public analyst goes on CNBC or the "Wall Street Journal" to give a "buy" or "sell" rating on a particular stock, they take all their research and pare it down into a simple designation. While there's no true consensus on what constitutes a buy or sell rating, an analyst usually does have "skin in the game" when devising ratings.

Ratings often pair with price targets, which put a hard number on what the analysts believe the company stock should be worth. So, for example, you might see an analyst report something like, "Buy NVIDIA Inc. (NASDAQ: NVDA), price target $350," which means that particular analyst believes investors should buy NVDA shares up to a price of $350 per share.

Analyst ratings infographic: What you need to know

What Does a Stock Analyst Do?

A stock analyst is a market professional with the skills to interpret financial data and the connections within companies to speak on the record with higher-ups. Analysts generally fall into one of two different camps: buy-side or sell-side. These positions will seem similar, but they tend to be employed by various institutions and have different responsibilities in their particular market "territories."

Buy-side analysts: Analysts on the buy side tend to work for funds, such as ETF providers or hedge funds. They don't dig as deeply into company financial data or conference calls as sell-siders. Instead, they focus on general areas or industries where their funds have vested interests. In addition, buy-side analysts often forge relationships with sell-side analysts for individual stock research. A buy-side analyst's primary goal is to find and utilize the most accurate and dependable sell-side analysts.
Sell-side analysts: If buy-side analysts work for funds (i.e., institutions that buy securities), you can probably guess which type of institution employs sell-side analysts. Brokers, banks and other firms that sell securities to investors use sell-side analysts to give reports to the public. While buy-side analysts also give ratings and price targets, the reported "buy" and "sell" ratings in financial media typically come from folks on the sell side.

Buy and sell-side analysts often use different rating systems when making their recommendations. You might even find two sell-side analysts with similar "buy" recommendations with vastly different price targets in the same stock. As a result, you'll need to familiarize yourself with the various methodologies analysts use to utilize their research correctly.

What Ratings Do Analysts Give?

Stock analyst ratings don't follow a strict structure, although most have roughly the same grading system for the securities they review. The labels may differ slightly (i.e., overweight vs. outperform), but the five most common analyst ratings go like this.

Buy

Analysts bullish on a particular security will give it a "buy" rating and set a price target above the current market price. In addition, if the analyst considers the stock one of the best in the industry or sector, you'll sometimes see a "strong buy" rating attached.

Hold

A "hold" rating is typically the lowest rating a sell-side analyst gives a stock. "Hold" means the analyst projects the stock to meet the return of the market averages, making it an unspectacular investment. Stocks rated "hold" may still have a price target above the current price, but it's not likely to surpass the return of a major index like the S&P 500.

Sell

Analysts are usually apprehensive about giving a stock a "sell" rating. For example, suppose a "hold" rating indicates indecision over the stock's future. In this scenario, a "sell" rating is issued when an analyst finds something unappealing, such as questionable accounting tactics or cratering sales growth.

Underperform

Analysts won't always give a firm "buy" or "sell" rating on stock but will instead label it "underperform" or "outperform." "Underperform" means the analyst expects the stock not to keep up with the market. It doesn't necessarily mean the analyst predicts a crash but indicates a lack of confidence in the shares.

Outperform

"Outperform" is the opposite of "underperform," meaning the analyst expects the stock to do better than the market average. It's usually considered a less confident rating than "buy."

Example of an Analyst Rating

You can use MarketBeat Analyst Ratings to find ranges and aggregates from buy- and sell-side analysts across the financial media. For example, here's a stock that analysts usually love: Alphabet Inc. (NASDAQ: GOOG).

Overview of stock analysis on GOOG Using MarketBeat's tools, you can find ratings from prominent analysts from multiple periods. Alphabet is currently labeled a "moderate buy" based on MarketBeat's consensus from 17 analysts. You'll get the consensus price target and the highest and lowest from the analysts surveyed.

Marketbeat's tools detailing analyst ratings

Looking at analyst recommendations over time is another helpful tool. For example, you can view the different levels of coverage over the last few years, which analysts changed their ratings and how the price targets vary from month to month. If an analyst can't get a good read on a particular stock they've been covering, they might choose to withhold their grade, which is one reason why the number of available ratings can change over time.

Overview of analyst ratings on MarketBeat Analysts from both sides of the aisle can be found on MarketBeat, ranging from large firms like JPMorgan Chase and Co. (NYSE: JPM) to smaller investment banks like Roth Capital. Some institutions like UBS Group offer both buy-side and sell-side ratings and analysis. These graphs show that even analysts with similar ratings can have vastly different price targets, so always understand the reasoning behind an analyst's view.

How to Use Analyst Ratings

Here are a few pointers on incorporating analyst ratings into your investment research.

Step 1: Don't rely on a single analyst.

Using an array of analysts (buy- and sell-side) gives inventors the most possible information. Don't just look for analysts with similar opinions as yourself — ensure you understand the pros and cons of each investment you make by incorporating positive and negative views, if possible.

Step 2: Compare analyst ratings across the industry or sector.

It's easy to slap a "buy" rating on a stock and predict a winner, but comparing stocks against others in the sector can offer insight into the rating. For example, if a stock is rated "buy" in the information technology sector, but a dozen others are rated "strong buy" by the same analyst, where is your capital best served?

Step 3: Consider your own goals and risk tolerance.

You might find stocks rated "strong buy" in your research in sectors you wish to avoid. That's fine! There are thousands of securities across dozens of industries in the public markets, and you don't need to purchase every share that comes with a "buy" rating. Instead, stick to your investment plan.

Step 4: Don't stubbornly stick to your original assessments.

Following your investment plan and using analyst ratings as guidelines are practical steps, but things can change over time. Today's "strong buy" stocks could be "strong sell" stocks down the road. Using an aggregate of analysts' ratings can help investors view stocks from a higher level. For example, if the number of "buy" ratings on a stock drops 40% over a few years, you might want to take a closer look at that particular company.

Why Are Analyst Ratings Important?

Checking out analyst ratings isn't a necessary step for investing, but it can be helpful for those looking to dig deep into an asset's prospects. Analyst research often has quotes from company executives, questions from conference calls and in-depth reporting on the company's balance sheet, income statement and other essential documents. Analysis like this is complex for individual investors to do on their own, especially considering how frequently analysts interact with the executives they cover. But access often comes with a downside, which we discuss more below.

How Accurate Are Analyst Ratings?

Both buy and sell-side analysts strive for accuracy because giving consistently wrong commendations can be hazardous for job security. However, investors should be aware that analysts might not always have the best interest of the retail investor at heart when making their recommendations.

For starters, being an analyst requires access to company employees and management. Analysts typically ask questions during conference calls and speak with C-suite executives on the record about their firms' prospects. Executives usually don't want to hear adverse reports about their companies, so analysts are incentivized to paint a rosy picture to retain access. The SEC has been questioning the authenticity of analyst ratings (especially on the sell-side) since 2002 when it asked bluntly, "Why are there so few sell ratings?"

Of course, there are other areas of the securities analysis market to face scrutiny. If you recall, during the 2008 financial crisis, the biggest credit rating agencies were all held to the fire due to claims that conflicts of interest influenced their ratings. The biggest rating agencies in the world were accused of "misrepresenting the risks associated with mortgage-backed securities." Remember, analyst ratings aren't spat out by computer algorithms but by living, breathing people who may have agendas other than providing the most precise and accurate reports on a company's future prospects.

Analyst Ratings Can Guide Investors, but Don't Treat Them as Gospel

Consider each type of investment research or advice in collaboration. Even the most accurate and thoughtful analysts get things wrong, plus ratings are frequently besieged with conflicts of interest. But analyst coverage does offer research that's difficult to get elsewhere, and using an array of analyst reports can give investors a deeper understanding of the securities they buy.

FAQs

Still have questions about analyst ratings? Here are a few answers to some common points of discussion:

What are analyst ratings?

Analyst ratings are the "buy" and "sell" labels, plus price targets, that investment researchers attach to specific securities. These ratings are based on financial data, earnings reports and conversations with company executives.

Should you trust analyst ratings?

Analyst ratings provide plenty of helpful information, but you shouldn't use an analyst's "buy" rating as the sole reason you purchase a security. Analysts aren't immune to conflicts of interest or outside parties' influence, so ensure you always understand why a stock was labeled a "buy" or "sell."

What does an analyst rating tell you about a stock?

Ratings give investors the analyst's overall opinion about a particular stock and price targets based on the company's valuation and prospects. Analysts often attend conference calls, ask questions and provide in-depth information about companies that are difficult to acquire elsewhere.

analyst ratings Headlines

Why Costco’s Rally May Continue Into 2025
By Thomas Hughes | December 17, 2024
View Why Costco’s Rally May Continue Into 2025
Broadcom: Turning the Mag 7 Into 8 Trillion-Dollar Tech Giants
By Thomas Hughes | December 13, 2024
View Broadcom: Turning the Mag 7 Into 8 Trillion-Dollar Tech Giants
Why Uber's Drop Could Be a Golden Entry Opportunity for 2025
By Sam Quirke | December 13, 2024
View Why Uber's Drop Could Be a Golden Entry Opportunity for 2025
Guidewire Software Provides Long-Awaited Buying Opportunity
By Thomas Hughes | December 8, 2024
View Guidewire Software Provides Long-Awaited Buying Opportunity
What’s Behind These 3 Recent Analyst Stock Upgrades?
By Gabriel Osorio-Mazilli | December 8, 2024
View What’s Behind These 3 Recent Analyst Stock Upgrades?
Okta: Bullish Signals Suggest a Market Reversal Is Underway
By Thomas Hughes | December 5, 2024
View Okta: Bullish Signals Suggest a Market Reversal Is Underway
Zoom Video Communications Positioned for Growth in 2025
By Thomas Hughes | December 3, 2024
View Zoom Video Communications Positioned for Growth in 2025

Top Headlines and Offers

View All

2 Underrated Quantum Computing Companies Starting to Rally
By Nathan Reiff | December 20, 2024
View 2 Underrated Quantum Computing Companies Starting to Rally
AI’s Next Big Winners: 3 Small-Cap Stocks to Watch in 2025
By Leo Miller | December 19, 2024
View AI’s Next Big Winners: 3 Small-Cap Stocks to Watch in 2025
Nvidia’s Bold Move: Tackling Tech’s $1 Trillion Crisis
From Weiss Ratings(Ad)
View Nvidia’s Bold Move: Tackling Tech’s $1 Trillion Crisis
Broadcom’s Stellar Outlook Sparks Hopes for a Semi Sector Rally
By Ryan Hasson | December 17, 2024
View Broadcom’s Stellar Outlook Sparks Hopes for a Semi Sector Rally
Micron Stock Under $100: Seize the AI-Driven Upside
By Thomas Hughes | December 19, 2024
View Micron Stock Under $100: Seize the AI-Driven Upside
Semtech Stock Climbs as AI Boom Drives Turnaround Success
By Jea Yu | December 16, 2024
View Semtech Stock Climbs as AI Boom Drives Turnaround Success
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
From Crypto Swap Profits(Ad)
View URGENT: This Altcoin Opportunity Won’t Wait – Act Now
Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon
By Leo Miller | December 18, 2024
View Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon
3 Companies Leading the Way With Aggressive Stock Buybacks
By Gabriel Osorio-Mazilli | December 16, 2024
View 3 Companies Leading the Way With Aggressive Stock Buybacks
Dave & Buster’s: Is It Time to Make Another Play on This Stock?
By Thomas Hughes | December 15, 2024
View Dave & Buster’s: Is It Time to Make Another Play on This Stock?
Trump was poised to inherit a strong economy. Then things got rocky and he added to the uncertainty
By The Associated Press | December 20, 2024
View Trump was poised to inherit a strong economy. Then things got rocky and he added to the uncertainty
AppLovin Insiders Sell Shares: Stock Price Indicated Higher
By Thomas Hughes | December 17, 2024
View AppLovin Insiders Sell Shares: Stock Price Indicated Higher

Stock Forecasts and Research Tools

Today's Ratings

Top Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Stock Price Targets and Analyst Ratings